



Appointment of Company Secretary

Brisbane, 29th of September 2016. Factor Therapeutics Limited (ASX : FTT) is pleased to announce the appointment of Melanie Farris AGIA, ACIS as Company Secretary, effective 29th of September 2016.

Ms Farris is experienced in governance, company and board administration, operations and communications with a strong track record across life sciences, investment and not-for-profit sectors. Current and previous roles include with Invion Limited (ASX:IVX), HRH The Prince of Wales's Office, Global Asset Management, Imperial Cancer Research Fund, and The Prince's Foundation.

Melanie holds a Bachelor of Communication (Public Relations) and a Graduate Diploma in Applied Corporate Governance. She is an Associate of the Governance Institute of Australia, and an Associate of the Institute of Chartered Secretaries and Administrators (UK).

The appointment of Melanie as Company Secretary comes at a time of significantly increased operational activity for Factor Therapeutics. Previously Ms Saskia Jo held both the role of Company Secretary and Finance Director. Saskia's increased responsibility and activity profile as Finance Director, particularly during the initiation of the company's Phase II trial in the US, warrants the additional human resources.

Corporate Contact

Dr. Christian P. Behrenbruch
Executive Director
Factor Therapeutics Limited
@: c.behrenbruch@factor-therapeutics.com

Investor Relations Contact

Kyahn Williamson
Head of Investor Communication
WE Buchan
@: kwilliamson@buchanwe.com.au

About Factor Therapeutics

Factor Therapeutics Limited ("Factor") is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company's platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology, Australia. Factor's shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit www.factor-therapeutics.com.

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available. This document may not be distributed or released in the United States.

Level 19,
179 Turbot Street
Brisbane QLD Australia 4000

phone +61 7 3334 3900
fax +61 7 3334 3999

GPO Box 1596
Brisbane QLD Australia 4001

www.factor-therapeutics.com